Crispr Therapeutics price target raised to $80 from $61 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics to $80 from $61 and keeps an Equal Weight rating on the shares post the Q4 report. The Q4 update largely incremental, with on-track pipeline progress, the analyst tells investors in a research note.